Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice

Valentina Sini, Saverio Cinieri, Michelino De Laurentiis, Angelo D. Leo, C. Tondini

Research output: Contribution to journalArticlepeer-review

Abstract

Current international guidelines recommend endocrine therapy as the initial treatment of choice in hormone receptor positive advanced breast cancer. Endocrine therapy has been a mainstay of hormone responsive breast cancer treatment for more than a century. To date it is based on different approaches,such as blocking the estrogen receptor through selective receptor estrogen modulators, depleting extragonadal peripheral estrogen synthesis by aromatase inhibitors or inducing estrogen receptor degradation using selective down-regulators.Despite estrogen and/or progesterone receptor positive status, up to a quarter of patients could be either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Different mechanisms, either intrinsic or acquired, could be implicated in endocrine resistance.In the present work available endocrine therapies and their appropriate sequences have been reviewed, and the most promising strategies to overcome endocrine resistance have been highlighted.

Original languageEnglish
Pages (from-to)57-68
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume100
DOIs
Publication statusPublished - Apr 1 2016

Keywords

  • Advanced breastcancer
  • Endocrine resistance
  • Endocrine therapy
  • Hormone receptor positive
  • Maintenance
  • Postmenopausal
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice'. Together they form a unique fingerprint.

Cite this